New drug ENA-001 tested for safety in first human study
NCT ID NCT06967259
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called ENA-001 in 36 healthy adults to see if it is safe and how the body processes it. Participants receive a single dose either through a vein or as a shot. The goal is to gather safety information before testing it in patients with respiratory depression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinilabs
ACTIVE_NOT_RECRUITINGEatontown, New Jersey, 07724, United States
-
Dr. Vince Clinical Research
COMPLETEDOverland Park, Kansas, 66212, United States
-
South Florida Research Phase I-IV
RECRUITINGMiami, Florida, 33166, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new painkiller prevent breathing crises after surgery?
- Wireless monitors could catch deadly breathing lapses after surgery
- Can a smart pump make Post-Surgical pain relief safer?
- Smart pain pump could stop Opioid-Induced breathing trouble
- Can a tiny electric zing prevent opioid breathing trouble?
- Ketamine may help ICU patients breathe easier on ventilators